Work

Phase 2 study of CT-322, a targeted biologic inhibitor of VEGFR-2 based on a domain of human fibronectin, in recurrent glioblastoma

Year: 2014

Type: article

Study design: Clinical Trial

Source: Investigational New Drugs

DOI: 10.1007/s10637-014-0186-2

Authors: David Schiff, Santosh Kesari, John de Groot, Tom Mikkelsen, Jan Drappatz, Thomas Coyle, Lisa Fichtel, Bruce Silver, Ian Walters, David Reardon

Institutions: University of Virginia, Dana-Farber Cancer Institute, The University of Texas MD Anderson Cancer Center, Henry Ford Hospital, SUNY Upstate Medical University, Texas Oncology, Bristol-Myers Squibb (United States), Duke University

Language: English

Topic: Glioma Diagnosis and Treatment

Subfield: Genetics

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2121427407

FWCI: 2.251

Cites: 20

Cited by: 51

Related to: 10